Keywords: USA, FDA User Fees, Generics, GPhA, Funding, AstraZeneca
US generics group GPhA encouraged with initial dialogue on FDA User Fees; AstraZeneca backs increased funding for the agency
Article | 21 September 2010
Following last Friday’s public meeting with the US Food and Drug Administration concerning the generic drug user fee ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
